Neuvotion NeuStim commercialization advances as brain-computer interface research gains validation
Neuvotion links its fall NeuStim launch to a Nature Medicine brain-body interface study, while the implanted system remains investigational.
Medical Devices & Diagnostics
Pharma & Biotech
A promising eye cancer drug shrank tumors in phase 1, so why did Novartis stop developing DYP688?
DYP688 showed early activity and manageable toxicity in metastatic uveal melanoma, but Novartis has halted development despite the clinical signal.
Pharma & Biotech
What Actuate Therapeutics’ Phase 2 survival data means for pancreatic oncology
Read how Actuate Therapeutics’ elraglusib survival data could reshape first-line pancreatic cancer treatment and what regulators may watch next.